ArticleScientific reports2018
An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 59 citations in OpenAlex.
- DNA methylation profiling identifies long-range epigenetic silencing of clustered protocadherins as a key determinant of meningioma progression.Nature communications · 2026Article
- Article
- Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas.Acta neuropathologica communications · 2025Article
- Determining the Biological Features of Aggressive Meningioma Growth with Transcriptomic Profiling.Cancers · 2025Article
- Review
- Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients.Neuro-oncology · 2024Review
- Meningioma recurrence: Time for an online prediction tool?Surgical neurology international · 2024Review
- Normal meninges harbor oncogenic somatic mutations in meningioma-driver genes.Acta neuropathologica · 2023Article
- Respective roles of Pik3ca mutations and cyproterone acetate impregnation in mouse meningioma tumorigenesis.Cancer gene therapy · 2023Article
- Gene expression analysis during progression of malignant meningioma compared to benign meningioma.Journal of neurosurgery · 2023Article
- DNA methylation provides diagnostic value for meningioma recurrence in clinical practice.Acta neurochirurgica · 2023Article
- Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories.Brain pathology (Zurich, Switzerland) · 2023Article
- Advances in Central Nervous System Tumor Classification.Advances in experimental medicine and biology · 2023Article
- Brain Invasion and Trends in Molecular Research on Meningioma.Brain tumor research and treatment · 2023Review
- Identification of key genes of anti-programmed death ligand 1 for meningioma immunotherapy by bioinformatic analysis.Medical oncology (Northwood, London, England) · 2022Article
- Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.Acta neurochirurgica · 2022Article
- Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.Neurologia medico-chirurgica · 2022Review
- A molecularly integrated grade for meningioma.Neuro-oncology · 2022Article
- Genetic analysis of a malignant meningioma and associated metastases.Acta neurochirurgica · 2022Article
- Chromatin Mechanisms Driving Cancer.Cold Spring Harbor perspectives in biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 14 institutions in 7 countries.
Grace CollordWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.ORCID 0000-0003-1924-4411
Patrick TarpeyWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Natalja KurbatovaEuropean Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, CB10 1SD, UK.ORCID 0000-0002-3973-2909
Inigo MartincorenaWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Sebastian MoranCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Manuel CastroCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Tibor NagyWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.ORCID 0000-0002-4451-0796
Graham BignellWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Francesco MauraWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Matthew D YoungWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Jorge BernaMobile Genomes and Disease, Molecular Medicine and Chronic diseases Centre (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, 15706, Spain.
Jose M C TubioMobile Genomes and Disease, Molecular Medicine and Chronic diseases Centre (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, 15706, Spain.
Chris E McMurranDepartment of Neurosurgery, Department of Clinical Neuroscience, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.ORCID 0000-0002-8710-0930
Adam M H YoungDepartment of Neurosurgery, Department of Clinical Neuroscience, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Mathijs SandersWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Imran NooraniWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Stephen J PriceDepartment of Neurosurgery, Department of Clinical Neuroscience, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
Colin WattsDepartment of Neurosurgery, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Elke LeipnitzKlinik und Poliklink für Neurochirurgie, "Carl Gustav Carus" Universitätsklinikum, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Matthias KirschKlinik und Poliklink für Neurochirurgie, "Carl Gustav Carus" Universitätsklinikum, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Gabriele SchackertKlinik und Poliklink für Neurochirurgie, "Carl Gustav Carus" Universitätsklinikum, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Danita PearsonDepartment of Pathology, Cambridge University Hospital, CB2 0QQ, Cambridge, UK.
Abel DevadassDepartment of Pathology, Cambridge University Hospital, CB2 0QQ, Cambridge, UK.
Zvi RamDepartment of Neurosurgery, Tel-Aviv Medical Center, Tel-Aviv, Israel.
V Peter CollinsDepartment of Pathology, Cambridge University Hospital, CB2 0QQ, Cambridge, UK.
Kieren AllinsonDepartment of Pathology, Cambridge University Hospital, CB2 0QQ, Cambridge, UK.
Michael D JenkinsonDepartment of Neurosurgery, The Walton Centre, Liverpool, L9 7LJ, UK.
Rasheed ZakariaDepartment of Neurosurgery, The Walton Centre, Liverpool, L9 7LJ, UK.
Khaja SyedDepartment of Neurosurgery, The Walton Centre, Liverpool, L9 7LJ, UK.
C Oliver HanemannInstitute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth University, Plymouth, Devon, PL4 8AA, UK.
Jemma DunnInstitute of Translational and Stratified Medicine, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth University, Plymouth, Devon, PL4 8AA, UK.
Michael W McDermottDepartment of Neurosurgery, UCSF Medical Center, San Francisco, CA, 94143-0112, USA.
Ramez W KirollosDepartment of Neurosurgery, Department of Clinical Neuroscience, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK.
George S VassiliouWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Manel EstellerCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.
Sam BehjatiWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Alvis BrazmaEuropean Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, CB10 1SD, UK.
Thomas SantariusDepartment of Neurosurgery, Department of Clinical Neuroscience, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK. ts381@cam.ac.uk.
Ultan McDermottWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK. um1@sanger.ac.uk.ORCID 0000-0001-9032-4700
Cambridge University Hospitals NHS Foundation Trust · GBUniversity of Cambridge · GBWellcome Sanger Institute · GBUniversity of Liverpool · GBKlinik und Poliklinik für Psychotherapie und Psychosomatik · DEEuropean Bioinformatics Institute · GBInstitut d'Investigació Biomédica de Bellvitge · ESUniversidade de Santiago de Compostela · ESUniversity of Plymouth · GBErasmus MC · NLInstitució Catalana de Recerca i Estudis Avançats · ESUniversity of Birmingham · GBUniversity of California San Francisco Medical Center · USUniversity of Milan · IT
Funding
Cancer Research UK 21777Cancer Research UK 23015Medical Research Council MC_PC_12009Wellcome TrustWellcome Trust WT098051
Abstract
Anaplastic meningioma is a rare and aggressive brain tumor characterised by intractable recurrences and dismal outcomes. Here, we present an integrated analysis of the whole genome, transcriptome and methylation profiles of primary and recurrent anaplastic meningioma. A key finding was the delineation of distinct molecular subgroups that were associated with diametrically opposed survival outcomes. Relative to lower grade meningiomas, anaplastic tumors harbored frequent driver mutations in SWI/SNF complex genes, which were confined to the poor prognosis subgroup. Aggressive disease was further characterised by transcriptional evidence of increased PRC2 activity, stemness and epithelial-to-mesenchymal transition. Our analyses discern biologically distinct variants of anaplastic meningioma with prognostic and therapeutic significance.
Indexed as
Gene Expression Regulation, NeoplasticAgedDisease ProgressionDNA MethylationFemaleGene Expression ProfilingGenomicsHumansMaleMeningeal NeoplasmsMeningiomaMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalPrognosisSurvival Analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.